



**Total Triiodothyronine (Total T3 SBS)
Test System
Product Code: 8175-300**

1.0 INTRODUCTION

Intended Use: The Quantitative Determination of Total Triiodothyronine in Human Serum or Plasma sample by a Micropate Enzyme Immunoassay, Chemiluminescence

2.0 SUMMARY AND EXPLANATION OF THE TEST

Measurement of serum triiodothyronine concentration is generally regarded as a valuable tool in the diagnosis of thyroid dysfunction. This importance has provided the impetus for the significant improvement in assay methodology that has occurred in the past. The advent of monoclonic antiserum and the discovery of blocking agents to the tT3 binding serum proteins have enabled the development of procedurally simple radioimmunoassay.^{1,2}

This microplate immunoassay methodology provides the technician with optimum sensitivity, while requiring few technical manipulations. In this method, a sample (Calibrators, Controls and Patient Specimen) is added to the streptavidin coated microwells of a 96 well microplate followed by Tracer (HRP) labeled tT3 derivative and biotin labeled purified anti-tT3 specific sheep IgG. A competition occurs between the varying amounts of tT3 in the sample and fixed amount of tT3 analog for a fixed number of binding sites on the antibody.

After the completion of the required incubation period, the antibody bound tT3-enzyme conjugate is separated from the unbound tT3-enzyme derivative by aspiration or decantation. The activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce light.


The employment of several serum references of known triiodothyronine concentration permits construction of a graph of activity and concentration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with tT3 concentration.

3.0 PRINCIPLE

Competitive Enzyme Immunoassay – Type 7

The essential reagents required for a chemiluminescence immunoassay include antibody, enzyme-antigen conjugate, native antigen and a substrate that produces light.

Upon mixing biotinylated antibody, enzyme-antigen conjugate and a serum containing the native antigen, a competition reaction results between the native antigen and the enzyme-antigen conjugate for a limited number of antibody binding sites. The interaction is illustrated by the following equation:



Ab_{Bn} = Anti-tT3-IgG labeled with biotin (Constant Quantity)
Ag = Native Antigen (Variable Quantity)

Enz Ag = Enzyme-antigen Conjugate (Constant Quantity)
AgAb_{Bn} = Antigen-Antibody Complex
Enz AgAb_{Bn} = Enzyme-antigen Conjugate - Antibody Complex
k_a = Rate Constant of Association
k_{-a} = Rate Constant of Disassociation
K = k_a / k_{-a} = Equilibrium Constant

A simultaneous reaction between the biotin attached to the antibody and the streptavidin immobilized on the microwell occurs. This effects the separation of the antibody bound fraction after decantation or aspiration.

AgAb_{Bn} + Enz AgAb_{Bn} + Streptavidin_{CW} ⇒ immobilized complex
Streptavidin_{CW} = Streptavidin immobilized on well
Immobilized complex = sandwich complex bound to the solid surface

The enzyme activity in the antibody bound fraction is measured by reaction with a suitable substrate to produce light, which is inversely proportional to the native antigen concentration. By utilizing several different serum references of known antigen concentration, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

4.0 REAGENTS

Materials Provided:

- A. Strept T3 Calibrators - 1ml/vial - Icons A-F**
Six (6) vials of serum reference for triiodothyronine at concentrations of 0 (A), 0.5 (B), 1.0 (C), 2.5 (D), 5.0(E) and 7.5(F) ng/ml. A preservative has been added. Store at 2-8°C. For SI units: ng/ml x 1.536 = nmol/L
- B. Strept T3 Tracer Reagent – 1.5ml/vial - Icon**
One (1) vial of T3 Analog-horse radish peroxidase (HRP) conjugate in an albumin-stabilizing matrix. A preservative has been added. Store at 2-8°C
- C. s-T3/T4 Tracer Buffer - 13ml/vial - Icon**
One (1) vial reagent contains buffer, red dye, preservative, and binding protein inhibitors. Store at 2-8°C.
- D. Strept T3 Biotin Reagent – 7 ml/vial – Icon**
One (1) vial contains biotinylated anti-triiodothyronine (sheep) reagent in a protein-stabilized matrix. A preservative has been added. Store at 2-8°C.
- E. Light Reaction Wells – 96 wells – Icon**
One 96-well microplates coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C.
- F. Wash Solution Concentrate -- 20ml/vial - Icon**
One (1) vial contains a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.
- G. Signal Reagent A – 7ml/vial - Icon S^A**
One (1) vial contains Luminol in buffer. Store at 2-8°C. See "Reagent Preparation."
- H. Signal Reagent B – 7ml/vial - Icon S^B**
One (1) vial contains hydrogen peroxide (H₂O₂) in buffer. Store at 2-8°C. See "Reagent Preparation."
- I. Product Insert.**

Note 1: Do not use reagents beyond the kit expiration date.
Note 2: Avoid extended exposure to heat and light. **Opened reagents are stable for sixty (60) days when stored at 2-8°C.**
Note 3: Above reagents are for a single 96-well microplate.

4.1 Required But Not Provided:

- 1. Pipette capable of delivering 0.050 & 0.100ml (50 & 100µl) volumes with a precision of better than 1.5%.
- 2. Dispenser(s) for repetitive deliveries of 0.100 & 0.350ml (100 & 350µl) volumes with a precision of better than 1.5%.
- 3. Adjustable volume (20-200µl) and (200-1000µl) dispenser(s) for conjugated dilutions.
- 4. Microplate washer or a squeeze bottle (optional).
- 5. Microplate Luminometer
- 6. Test tubes for dilution of tracer conjugate and mixing the signal reagents A and B.
- 7. Absorbent Paper for blotting the microplate wells.
- 8. Plastic wrap or microplate covers for incubation steps.
- 9. Vacuum aspirator (optional) for wash steps.
- 10. Timer.
- 11. Quality control materials.

5.0 PRECAUTIONS

For In Vitro Diagnostic Use

Not for Internal or External Use in Humans or Animals

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA required tests. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

Safe disposal of kit components must be according to local regulatory and statutory requirement.

6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood, serum or plasma in type, and the usual precautions in the collection of venipuncture samples should be observed. For accurate comparison to established normal values, a fasting morning serum sample should be obtained. The blood should be collected in a redtop venipuncture tube with or without additives (for serum) or evacuated tube(s) containing EDTA or heparin (for plasma). Allow the blood to clot for serum samples. Centrifuge the specimen to separate the serum or plasma from the cells.

In patients receiving therapy with high biotin doses (i.e. >5mg/day), no sample should be taken until at least 8 hours after the last biotin administration, preferably overnight to ensure fasting sample.

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.100ml (100µl) of the specimen is required for Total T3.

7.0 QUALITY CONTROL

Each laboratory should assay external controls at levels in the hypothyroid, euthyroid and hyperthyroid range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. The individual laboratory should set acceptable assay performance limits. In addition, maximum light intensity should be consistent with past experience. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

8.0 REAGENT PREPARATION

- 1. Working Tracer - tT3-enzyme Conjugate Solution**
Dilute the tT3 Tracer Reagent 1:11 with sT3/T4 buffer in a suitable container. For example, dilute 0.080ml (80µl) of conjugate with 0.800ml (800 µl) of buffer for 16 wells (a slight excess of solution is made). This reagent should be used within twenty-four hours for maximum performance of the assay. Store at 2-8°C.
General Formula:
Amount of Buffer required = Number of wells * 0.05
Quantity of tT3 Tracer necessary = # of wells * 0.005
i.e. = 16 x 0.05 = 0.8ml (80µl) (sT3/T4 Buffer) and 16 x 0.005 = 0.08ml (80µl) (tT3 Tracer Reagent).
- 2. Wash Buffer**
Dilute contents of Wash Concentrate to 1000ml with distilled or deionized water in a suitable storage container. Store diluted buffer at 2-30°C for up to 60 days.
- 3. Working Signal Reagent Solution - Store at 2 - 8°C.**
Determine the amount of reagent needed and prepare by mixing equal portions of Signal Reagent A and Signal Reagent B in a clean container. For example, add 1 ml of A and 1ml of B per two (2) eight well strips (A slight excess of solution is

made). **Discard the unused portion if not used within 36 hours after mixing.** If complete utilization of the reagents is anticipated, within the above time constraint, pour the contents of Signal Reagent B into Signal Reagent A and label accordingly.

Note: Do not use reagents that are contaminated or have bacteria growth.

9.0 TEST PROCEDURE

*Before proceeding with the assay, bring all reagents, serum reference calibrators and controls to room temperature (20-27°C). ****Test procedure should be performed by a skilled individual or trained professional*****

- 1. Format the microplates' wells for each serum calibrator, control and patient specimen to be assayed in duplicate. **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.**
- 2. Pipette 0.050ml (50µl) of the appropriate serum reference calibrator, control or specimen into the assigned wells.
- 3. Add 0.050ml (50µl) of Working Tracer Reagent solution to the appropriate wells (see Reagent Preparation Section).
- 4. Swirl the microplate gently for 20-30 seconds to mix and cover.
- 5. Add 0.050ml (50µl) of biotinylated Total T3 specific antibody conjugate solution to the appropriate wells.
- 6. Swirl the microplate gently for 20-30 seconds to mix and cover.
- 7. Incubate 45 minutes at room temperature.
- 8. Add 0.350ml (350µl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat four (4) additional times for a total of five (5) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat four (4) additional times.**
- 9. Add 0.100ml (100µl) of working signal reagent solution to all wells (see Reagent Preparation Section). **Always add reagents in the same order to minimize reaction time differences between wells.**
DO NOT SHAKE PLATE AFTER SIGNAL ADDITION
- 10. Incubate for five (5) minutes in the dark at room temperature
- 11. Read the Relative Light Units (RLUs) in each well, for minimum 0.5 – 1.0 seconds, using a microplate luminometer. **The results should be read within thirty (30) minutes of adding the signal solution.**

Note: For re-assaying specimens with concentrations greater than 7.5 ng/ml, pipette 0.025ml (25µl) of the specimen and 0.025ml (25µl) of the "0" serum reference into the sample well (this maintains a uniform protein concentration). Multiply the readout value by 2 to obtain the triiodothyronine concentration.

10.0 CALCULATION OF RESULTS

A dose response curve is used to ascertain the concentration of triiodothyronine in unknown specimens.


- 1. Record the RLUs obtained from the printout of the microplate reader as outlined in Example 1.
- 2. Plot the RLUs for each duplicate serum reference versus the corresponding tT3 concentration in ng/ml on linear graph paper.
- 3. Draw the best-fit curve through the plotted points.
- 4. To determine the concentration of tT3 for an unknown, locate the average RLUs for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in ng/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average RLUs (63817) of the unknown intersects the calibration curve at (1.4 ng/ml) tT3 concentration (See Figure 1).

Note 1: Computer data reduction software designed for chemiluminescence assays may also be used for the data reduction. **If such software is utilized, the validation of the software should be ascertained.** Duplicates of the unknown may be averaged as indicated (See Figure 1).

EXAMPLE 1

Sample I.D.	Well Number	RLU (A)	Mean RLU (B)	Value (ng/ml)
Cal A	A1	100468	100000	0
	B1	99532		
Cal B	C1	88644	86989	0.5
	D1	85333		
Cal C	E1	71996	72275	1.0
	F1	72553		
Cal D	G1	46658	45952	2.5
	H1	45247		
Cal E	A2	26556	26887	5.0
	B2	27219		
Cal F	C2	19549	18710	7.5
	D2	17871		
Ctrl 1	E2	71096	71745	1.0
	F2	72393		
Ctrl 2	G2	49482	49732	2.2
	H2	49981		
Patient	A3	64506	63817	1.4
	B3	63127		

FIGURE 1



*The data presented in Example 1 and Figure 1 is for illustration only and **should not** be used in lieu of a dose response curve prepared with each assay. In addition, the RLU of the calibrators have been normalized to 100,000 RLUsec for the A calibrator (greatest light output). This conversion minimizes differences caused by efficiency of the various instruments that can be used to measure light output

11.0 QC PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:

- The Dose Response Curve should be within established parameters.
- Four out of six quality control pools should be within the established ranges.

12.0 RISK ANALYSIS

The MSDS and Risk Analysis Form for this product are available on request from Monobind Inc.

12.1 Assay Performance

- It is important that the time of reaction in each well is held constant to achieve reproducible results.
- Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
- Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
- If more than one (1) plate is used, it is recommended to repeat the dose response curve.
- The addition of signal reagent initiates a kinetic reaction; therefore, the signal reagent(s) should be added in the same sequence to eliminate any time-deviation during reaction.
- Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
- Use components from the same lot. No intermixing of reagents from different batches.
- Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind IFU may yield inaccurate results.
- Multichannel pipettes are recommended for addition of reagents.

- All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.
- It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
- Risk Analysis- as required by CE Mark IVD Directive 98/79/EC - for this and other devices, made by Monobind, can be requested via email from Monobind@monobind.com.

12.2 Interpretation

- Measurements and interpretation of results must be performed by a skilled individual or trained professional.** Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
- The reagents for the test system procedure have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays. (Boscato LM Stuart MC. 'Heterophilic antibodies: a problem for all immunoassays' Clin.Chem. 1988:3427-33). For diagnostic purposes, the results from this assay should be used in combination with clinical examination, patient history and all other clinical findings.
- For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
- If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, Monobind shall have no liability.
- If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.
- Total serum triiodothyronine concentration is dependent upon a multiplicity of factors: thyroid gland function and its regulation, thyroxine binding globulin (TBG) concentration, and the binding of triiodothyronine to TBG.^{3,4} Thus, total triiodothyronine concentration alone is not sufficient to assess clinical status.
- A decrease in total triiodothyronine values is found with protein-wasting diseases, certain liver diseases and administration of testosterone, diphenylhydantoin or salicylates. A table of interfering drugs and conditions, which affect total triiodothyronine values, has been compiled by the Journal of the American Association of Clinical Chemists.⁵

13.0 EXPECTED RANGES OF VALUES

A study of euthyroid adult population was undertaken to determine expected values for Total T3 SBS AccuLite® CLIA test system. The mean (R) values standard deviations (σ) and expected ranges (±2σ) are presented in Table 1. The total number of samples was 85.

Expected Values for the Total T3 SBS Acculite® CLIA (in ng/ml)	
Mean (x)	1.22
Standard Deviation (σ)	0.35
Expected Ranges (±2σ)	0.52 – 1.98

It is important to keep in mind that establishment of a range of values, which can be expected to be found by a given method for a population of "normal" persons, is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons, each laboratory should depend upon the range of expected values established by the Manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

14.0 PERFORMANCE CHARACTERISTICS

14.1 Precision

The within and between assay precision of the Total T3 SBS AccuLite® CLIA test system was determined by analyses on three different levels of pool control sera. The number, mean values,

standard deviation and coefficient of variation for each of these control sera are presented in Table 2 and Table 3.

TABLE 2
Within Assay Precision (Values in ng/ml)

Sample	N	X	σ	C.V.
Low	16	0.85	0.058	6.8%
Normal	16	2.25	0.123	5.5%
High	16	3.20	0.134	4.2%

TABLE 3
Between Assay Precision (Values in ng/ml)

Sample	N	X	σ	C.V.
Low	10	0.81	0.068	8.4%
Normal	10	2.19	0.145	6.6%
High	10	3.32	0.176	5.3%

*As measured in ten experiments in duplicate over a ten day period.

14.2 Sensitivity

The Total T3 SBS AccuLite® CLIA Test System has a sensitivity of 0.04 ng/ml. The sensitivity was ascertained by determining the variability of the 0 ng/ml serum calibrator and using the 2σ (95% certainty) statistic to calculate the minimum dose.

14.3 Accuracy

The Total T3 SBS AccuLite® CLIA Test System was compared with a reference method. The least square regression equation and the correlation coefficient were computed for the CLIA in comparison with the reference methods. The data obtained are displayed in Table 4.

TABLE 4

Method	Mean (x)	Least Square Regression Analysis	Correlation Coefficient
Monobind	1.43	y = 0.062 + 0.957(x)	0.976
Reference	1.48		

Only slight amounts of bias between this method and the reference method are indicated by the closeness of the mean values. The least square regression equation and correlation coefficient indicates excellent method agreement.

14.4 Specificity

The cross reactivity of the antibodies used to selected substances was evaluated by adding the interfering substance to a serum matrix at various concentrations. The cross-reactivity was calculated by deriving a ratio between dose of interfering substance to dose of thyroid hormone needed to displace the same amount of tracer.

Substance	Cross Reactivity	Concentration
I-Triiodothyronine	1.0000	-
I-Thyroxine	< 0.0002	10µg/ml
Iodothyrosine	< 0.0001	10µg/ml
Diiodothyrosine	< 0.0001	10µg/ml
Diiodothyronine	< 0.0001	10µg/ml
Phenylbutazone	< 0.0001	10µg/ml
Sodium Salicylate	< 0.0001	10µg/ml

15.0 REFERENCES

- Gharib H., Ryan R.J., Mayberry W.E., & Hockett T., "Radioimmunoassay for Triiodothyronine (T3): Affinity and Specificity of Antibody for T3", *J Clinical Endocrinol*, 33,509 (1971).
- Chopra I.J., Ho R.S., & Lam R. "An improved radioimmunoassay of triiodothyronine in human serum", *J. Lab Clinical Med*, 80, 729 (1971).
- Young DS, Pestaner LC and Gilberman, "Effects of Drugs on Clinical Laboratory Tests", *Clinical Chemistry*, 21, 3660 (1975).
- Sterling L., "Diagnosis and Treatment of Thyroid Disease", *Cleveland CRC Press*, p. 9-51 (1975).
- Braverman LE.: "Evaluation of thyroid status in patients with thyrotoxicosis", *Clin Chem*, 42, 174-178 (1996).
- Braverman LE, Utigen RD, Eds.: *Werner and Ingbar's "The Thyroid - A Fundamental and Clinical Text"*, 7th Ed. Philadelphia, Lippincott-Raven (1996).
- Comeau L, P-ianan U, Leo-Mensah T, et al, "An automated chemiluminescent immunoassay test for total triiodothyronine", *Clin Chem*, 37, 941 (1991).

- Chopra I.J.: "Radioimmunoassay of iodothyronines-*Handbook of Radioimmunoassay*", G.E. Abraham Ed, New York, Marcel Dekker, Inc. (1977).
- Kozwick D, Davis G, Sockol C, "Development of total triiodothyronine enzyme immunoassay in microtiter plate format", *Clin Chem*, 37, 1040 (1991).
- Papanastasiou-Diamandi A., Khosravi M.: "Total T3 (triiodothyronine) measurement in serum by time resolved fluorescence immunoassay", *Clin Chem*, 7, 1029 (1991).

Revision: 3 Date: 2019-Jul-16 DCO: 1353
MP8175 Product Code: 8175-300

Size	96(A)	192(B)	480(D)	960(E)
Reagent (fill)	A) 1ml set	1ml set	2ml set	2ml set x2
	B) 1 (1.5ml)	2 (1.5ml)	1 (8ml)	2 (8ml)
	C) 1 (13ml)	2 (13ml)	1(60ml)	2 (60ml)
	D) 1 (7ml)	2 (7ml)	1 (30ml)	2 (30ml)
	E) 1 plate	2 plates	5 plates	10 plates
	F) 1 (20ml)	1 (20ml)	1 (60ml)	2 (60ml)
	G) 1 (7ml)	2 (7ml)	1 (30ml)	2 (30ml)
	H) 1 (7ml)	2 (7ml)	1 (30ml)	2 (30ml)

For Orders and Inquires, please contact

Monobind Inc.
100 North Pointe Drive
Lake Forest, CA 92630 USA

Tel: +1 949.951.2665 Mail: info@monobind.com
Fax: +1 949.951.3539 Fax: www.monobind.com



Please visit our website to learn more about our products and services.

Glossary of Symbols
(EN 980/ISO 15223)

